Estrella Immunopharma, Inc. (ESLA)
NASDAQ
0.4175
-0.0015 (-0.36%)
Closed
Oct 8, 2026
Day's Range
0.36110.4260
52 wk Range
0.36113.15
Financial Statements - ESLA - Estrella Immunopharma, Inc.
Revenue
0
Net Income
-13.06M▼ 78.7%
EBITDA
-13.06M▼ 78.7%
Free Cash Flow
-1.78M▲ 88.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
 Operating Expense | - | - | - | - | - |
| Operating Income | -13.06M | -7.31M | -11.11M | -1.68M | -733.69K |
| Non-Operating Interest | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - |
| Pre Tax Income | -13.06M | -7.31M | -11.11M | -1.68M | -733.69K |
| Income Tax | 838 | 1.62K | 0 | 0 | 0 |
| Net Income | -13.06M | -7.31M | -11.11M | -1.68M | -733.69K |
| EPS Basic | -0.35 | -0.27 | -0.315739 | -0.047878 | -0.020843 |
| EPS Diluted | -0.35 | -0.27 | -0.315739 | -0.047878 | -0.020843 |
| Basic Shares Outstanding | 36.82M | 27.10M | 35.20M | 35.20M | 35.20M |
| Diluted Shares Outstanding | 36.82M | 27.10M | 35.20M | 35.20M | 35.20M |
| Ebit | -13.06M | -7.31M | -11.11M | -1.68M | -733.69K |
| Ebitda | -13.06M | -7.31M | -11.11M | -1.68M | -733.69K |
| Net Income Continuous Operations | -13.06M | -7.31M | -11.11M | -1.68M | -733.69K |
| Minority Interests | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
